-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $35

Benzinga·03/19/2026 10:21:52
Listen to the news
Truist Securities analyst Richard Newitter upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and raises the price target from $27 to $35.